The Impact of Patient and Parents’ Education by Nurses on Serum Ferritin Levels in Children with Beta-Thalassemia Major by Aycicek, Ali et al.
48 Global Journal of Hematology and Blood Transfusion, 2016, 3, 48-53  
 
 E-ISSN: 2408-9877/16 © 2016 Cosmos Scholars Publishing House 
The Impact of Patient and Parents’ Education by Nurses on Serum 
Ferritin Levels in Children with Beta-Thalassemia Major 
Ali Aycicek1,*, Ahmet Koc2, Cengiz Bayram1 and Mahmut Abuhandan3 
1Kanuni Sultan Suleyman Research and Education Hospital, Pediatric Hematology/Oncology Clinic, 34303 
Istanbul Turkey 
2Marmara University Medical Faculty, Research Hospital, Pediatric Hematology/Oncology Department, 34890 
Istanbul, Turkey 
3Harran University Medical Faculty Pediatrics Department, 63050, Sanliurfa, Turkey 
Abstract: Background: Through education and information, nurses can help patients learn more about their health 
status and can contribute to improvement in patient drug adherence, clinical and laboratory outcomes. The aim of this 
study was to assess the impact of patient and their family education by nurses on serum ferritin levels. 
Methods: The study included 85 children with transfusion-dependent beta-thalassemia aged between 2.4 to 17 (mean 
7.6 ± 3.3) years, 44 (52%) of whom were male. All patients received deferasirox doses ranged from 12 to 40 mg/kg/day. 
Patients and their families were requested for education intervention provided by nurses. Seventeen patients (group 1) 
(11 male, 6 female) refused to receive education or not compliant with the study protocol. Sixty-eight (33 male, 35 
female) patients (group 2) and their parents educated by nurses, including drug instructions, telephone interviews and 
home visits for 12 months. 
Results: Mean deferasirox dose at the 24th and 36th months of the study were 31.6 ± 7 and 32 ± 8 mg/kg/day in group 1, 
and were 32.7 ± 8 and 33.6 ± mg/kg/day in group 2, respectively. Mean serum ferritin levels at the 24th and 36th months 
of the study were reduced from 4424 ± 2305 ng/mL to 3425 ± 1661 ng/mL (the mean difference was 662 ng/mL) (P 
=0.044) in group 1, and were reduced from 3177 ± 1645 to 2748 ± 1343 ng/mL (the mean difference was 274 ng/mL) (P 
= 0.033) in group 2, respectively  
Conclusion: Our study’s results suggested that patient and parents’ education by nurses have no significant impact in 
reducing ferritin levels in children with beta-thalassemia major. Deferasirox dose was the only significant predictor that 
contributed to reduction in ferritin levels. 
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INTRODUCTION 
Iron chelation therapy in patients with beta 
thalassemia major has led to the prevention of iron 
accumulation in addition to treating iron overload and 
iron-induced end-organ complications, which provided 
to achieve a normal pattern of complication-free 
survival and of quality of life [1].  
Deferasirox is a once-daily oral iron chelator that 
has proven to be effective in reducing liver and serum 
ferritin levels over 1 year in patients with various 
transfusion-dependent anemias [2-4]. We previously 
reported about the safety, tolerability and efficacy of 
deferasirox use in children, who received deferasirox 
for 3 years, with transfusion dependent beta-
thalassemia at Sanliurfa province located in the 
southeast region of Turkey [4]. The superiority of 
deferasirox over deferoxamine for treatment of iron 
burden lies in its oral preparation and its long half-life  
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that provides once a day dosage, which may contribute 
to reducing substantial long-term compliance problems 
[5]. Medication adherence is increasingly recognized as 
an important issue that has significant impact on the 
clinical course of disease and patient quality of life, 
Further, patients' adherence with their medication is 
poor especially in chronic diseases, including diabetes, 
coronary heart diseases, cancer and chronic 
hematological diseases such as beta-thalassemia 
major [5]. Because patients with chronic diseases are 
prone to develop serious complications associated with 
their illness, efforts must be focused on developing 
effective and efficient intervention strategies for early 
detection and prevention of these complications. One 
of the approaches to overcome this problem is patient 
education by nurses. As a healthcare provider, nurses 
may play a unique and important role in assisting 
patients to carry out healthy behaviour in the context of 
treatment adherence and achieving better clinical 
outcomes. In the current study, we aimed to highlight 
the importance of patient education by nurses and to 
establish whether it will provide a beneficial effect on 
ferritin levels in the context of adherence to chelation 
therapy in patients with beta thalassemia major. 
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MATERIALS AND METHODS 
The study included 85 children with transfusion-
dependent beta-thalassemia at Harran University 
Research Hospital Pediatric Hematology Department 
aged between 2.4 to 17 (mean 7.6 ± 3.3) years, 44 
(52%) of whom were male. All patients received 
deferasirox (Exjade®, Novartis). The assigned dose of 
deferasirox was administered as a suspension in water 
half an hour prior to breakfast 7 days a week. Children 
with beta-thalassemia major, aged ≥2 years, with 
serum ferritin levels greater than 1000 ng/mL and using 
deferasirox were eligible for inclusion in the study 
regardless of prior type of chelation treatment. Patients 
were excluded from this trial if they had one of the 
following conditions: undergone bone marrow 
transplantation, no regular follow-up visits, noncompli- 
ance with prescribed therapy, gastrointestinal 
conditions preventing absorption of an oral medication 
or concomitant conditions preventing therapy with 
deferasirox. Patients and their families were informed 
about beta thalassemia major and chelation therapy by 
pediatric physician assistant and pediatric hematologist 
at our Pediatric Hematology outpatient clinic. Blood 
transfusions were regularly administered during the 
study period according to the patients’ requirements. 
Laboratory analysis, carried out at Harran University 
Research Hospital Biochemistry Department, including 
complete blood count, electrolytes, liver function tests, 
serum creatinine and serum ferritin levels were 
performed at monthly intervals to assess safety and 
efficacy of chelation treatment. In addition to regular 
information given at Pediatric Hematology outpatient 
clinic, all patients and their families were requested for 
education intervention provided by certified and 
registered nurses, however, 17 patients (11 male, 6 
female) (group 1) refused to receive education or not 
compliant with the study protocol. Sixty-eight (33 male, 
35 female) patients and their parents (group 2) 
received education provided by nurses at outpatient 
transfusion center during regular blood transfusion of 
every 3-4 weeks, and followed by home visits and 
telephone contact for 12 months. 
Education intervention, based on prescribing 
information of Exjade®, the main points were as 
follows: 
1. Take the drug once daily on an empty stomach 
at least 30 minutes prior to food, preferably at 
the same time every day.  
2. Completely disperse the tablets in water, orange 
juice, or apple juice, and drink the resulting 
suspension immediately. After the suspension 
has been swallowed, resuspend any residue in a 
small volume of the liquid and swallow. 
3. Do not chew or swallow tablets whole. 
4. Do not take aluminum-containing antacids and 
Exjade simultaneously. 
5. There may have the risk of fatal and nonfatal 
gastrointestinal bleeding, ulceration, and irritation 
more frequently if Exjade is being taken by 
combination with drugs that have known 
ulcerogenic or hemorrhagic potential, such as 
NSAIDs, corticosteroids, oral bisphosphonates, 
or anticoagulants. 
6. Be cautious if Exjade is being taken by 
concomitantly with drugs that are potent UGT 
inducers (e.g., rifampicin, phenytoin, 
phenobarbital), drugs metabolized by CYP3A4 
(e.g., cyclosporine, simvastatin, hormonal 
contraceptive agents), which may potentially 
cause loss of effectiveness of Exjade and 
necessities to increase the dose of Exjade. 
7. Be cautious about the most frequently occurring 
(>5%) adverse reactions associated with Exjade 
use, which are diarrhea, vomiting, nausea, 
abdominal pain, skin rashes, and increases in 
serum creatinine, and if occured, contact doctor 
immediately. 
8. Be cautious about severe skin rashes that may 
occur during Exjade treatment, and if occurred, 
stop taking Exjade and contact doctor 
immediately. 
9. Store Exjade tablets at 25°C (room temperature), 
at 15°C-30°C while on excursion and protect 
from light and moisture. 
10. If a dose is missed, take it as soon as remember. 
If it is near the time of the next dose, skip the 
missed dose and resume usual dosing schedule. 
Do not double the dose to catch up. 
Upon conclusion of the sessions, the educator 
provides written curriculum reflecting current evidence 
and evaluating outcomes. There have not been any 
reports on patient compliance with an education 
prescription in real clinical practice. 
The study was approved by the local scientific 
ethics committee, and informed consent was obtained 
from the parents of the patients. 
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STATISTICAL METHODS 
The data were expressed as number (%), mean ± 
SD, median and range. The paired samples t-test was 
used to compare mean serum ferritin levels [95% 
confidence interval]. All statistical tests were two-sided 
and the level of statistical significance was set at P< 
0.05. Statistical analyses were performed using SPSS 
for Windows Release 11.5 (SPSS, Chicago, IL, USA).) 
RESULTS 
Mean deferasirox dose at the 0th, 12th, 24th and 
36th of the study was 20 ± 9 mg/kg/day, 24 ± 9 
mg/kg/day, 31 ± 8 mg/kg/day and 32 ± 8 mg/kg/day, 
respectively. Mean serum ferritin levels decreased 
slightly between 12th to14th months of the study, while 
progressive decrease in ferritin levels were achieved 
when the average actual dose of deferasirox increased 
to >30 mg/kg/day after 22th months of the study in all 
patients. Mean serum ferritin levels increased 
progressively during the first 22 months of treatment, 
from 3.152 ± 1.650 ng/mL to 3.373 ± 1.1818 ng/mL (P 
= 0.227), and then decreased gradually to 2.868 ± 
1.414 ng/mL (P = 0.004) at 36 months of the study for 
all studied patients (Figure 1). The mean age of the 
patients at the start of the study was 8.7 ± 4.2 years 
(range, 12–17 years; 11 male and 6 female) in group 1, 
and was 7.5 ± 4.2 years (range, 2–17 years; 33 male 
and 35 female) in group 2 (Table 1) (P > 0.05). Mean 
serum ferritin levels reduced from 3.130 ± 1.477 to 
2.749 ± 1.343 ng/mL (P = 0.044) (mean difference: 315 
± 751 ng/mL) in group 2 after education program and 
reduced from 4.221 ± 2.167 ng/mL to 3.425 ± 1.661 
ng/mL (P =0.033) (mean difference: 785 ± 826) in 
group 1 (Figure 2), despite the fact that they were not 
educated at the same period (Figure 3). At the end of 
the study, the rate of patients receiving deferasirox at a 
dose of ≤25 mg/kg/day showed a marked decrease; 
and the mean final dose of deferasirox was ~32 
mg/kg/day in most of the patients (Table 1). There was 
a significant decrease in ferritin level in patients with 
ferritin level >4.000 ng/mL in both groups. Forty-two 
percent of patients in group 1 and 45% of patients in 
group 2 maintained serum ferritin levels ≤2500 ng/mL 
at the end of treatment, respectively. 
Table 1: Demographics and Patient Characteristics of Deferasirox Treatment in the Groups 
 Group 1 (n = 17) Group 2 (n = 68) 
Characteristic Start of Education End of Education Start of Education End of Education 
Age, y     
Mean ± SD 8.7 ± 4.2‡ 11.8 ± 4.3 7.5 ± 4.2‡ 11.9 ± 4.2 
Sex (%)     
Male 11^ 11 33^ 33 
Female 6 6 35 35 
Serum Ferritin, ng/mL     
Mean  ± SD 4221 ± 2.167 3.425 ± 1.661 †** 3.130± 1.477 2.749 ± 1343†* 
Median (range) 
3.334  
(1.730-8.212) 
3.141 
(1.501 -6.428) 
2.648  
(1.284-7.827) 
2.494  
(470 -6.879) 
Mean difference, ng/mL - 785 ± 826 - 315 ± 751 
Serum Ferritin Category, %     
<1000 ng/mL 0 0 0 5 
1000-2500 ng/mL 25 42 48 45 
2501-4000 ng/mL 31 33 32 38 
>4000 ng/mL 44 25 20 12 
Deferasirox dosing, mg/kg/day 32.7 33.6 31.6 31.9 
‡ Student t-test (P = 0.310) 
†Paired sample t-test (*P = 0.033, **P = 0.044) 
^Chi-square test (P = 0.232) 
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Figure 1: Changes in serum ferritin levels in all children with 
beta-thalassemia. 
 
Figure 2: Changes in serum ferritin levels and deferasirox 
dose in group 1. 
 
Figure 3: Changes in serum ferritin levels and deferasirox 
dose in group 2. 
DISCUSSION 
The oral iron chelator deferasirox was approved in 
the USA in 2005, in Europe in 2006, and in Turkey in 
2007 for clinical use as a first-line therapy for blood-
transfusion-related iron overload, respectively. It is an 
orally ingested, highly bioavailable chelator that is 
absorbed in the gastrointestinal tract, and its dose-
dependent half life of 12 to 18 hours provides once a 
day dosage [6]. It is reported that daily use of a single 
oral dose of 20-30 mg/kg per day results in dose-
dependent decrease in serum ferritin [7, 9]. Cappelini 
et al. reported that a dose of 20 mg/kg was predicted to 
be able to maintain stable iron balance in regularly 
transfused patients [7]. However, in our previous study, 
deferasirox treatment at a mean dose of 24 ± 8 
mg/kg/day did not create a stable iron balance during 
the first year of the study, where as negative iron 
balance was achieved at a dose of ≥ 30 mg/kg/day 
during the third year of the study [4]. Taher et al. also 
reported that deferasirox doses ≥ 30 mg/kg/day were 
generally required because of high transfusional iron 
intake and high baseline serum ferritin levels, 
highlighting the importance of administering an 
adequate dose to achieve net negative iron balance 
[10]. However, a proportion of patients do not achieve 
net negative iron balance, even at a dose of 40 
mg/kg/day [11, 12] The efficacy of deferasirox was 
dependent on transfusional intake and optimal dose, 
highlighting the importance of timely dose adjustment 
in order to achieve clinical goals [13]. 
Because a growing number of patients prefer oral 
chelation therapy rather than intravenous 
administration, the issue of adherence is becoming 
increasingly important in patients with beta-thalassemia 
major as in other chronic disease treatment. Oral 
chemotherapy is cost effective, if it is taken as 
prescribed. However, if patients are non-adherent to 
medication, the cost burden of unused medicines is 
substantial [14]. In general, patients are considered to 
be adherent if the ≥80% of prescribed medication is 
taken timely and at an appropriate dose without 
missing dose or extra dose [15]. A number of factors 
are associated with medication adherence. There are 
three levels of barriers to adherence: patient, 
healthcare provider, and healthcare system levels [16]. 
The patient-related factors include health beliefs and 
socioeconomic factors, while communication and the 
complexity of the regimen are regarded as healthcare-
provider factors [15]. One of the approaches for 
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overcoming the problem of patient-related factors is 
patient education provided by nurses. There are 
barriers to effective patient education for nurses 
especially in crowded outpatient clinical setting [17]. 
Limited time for teaching, patients and their parents’ 
physical or psychological condition are important 
challenge for nurses that can limit the effectiveness of 
patient education in such crowded outpatient 
departments [18]. In this context, overuse of hospital 
outpatient departments in urban areas of developing 
countries, like our Pediatric Hematology Center in 
Turkey, is still perceived as a problem by many health 
planners. However, despite these challenges, our 
results showed that the current study’s patients and 
their parents, in both groups, were adherent to 
medications regardless of patient education 
interventions provided by nurse [19]. This is the first 
report evaluating the impact of patient education by 
nurses on drug adherence and ferritin levels in patients 
with beta thalassemia major receiving oral chelator. 
The major limitations of the current study were that 
patients number and mean ferritin levels were not 
similar for both groups.  
IN CONCLUSION 
Our results suggested that patients and their 
parents’ education by nurses did not provide a 
contribution in reducing serum ferritin level, deferasirox 
dose was the only significant predictor.  
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